Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Immunocytochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ALX-804-151-C100 - Provider product page
- Provider
- Enzo Life Sciences
- Proper citation
- Enzo Life Sciences Cat#ALX-804-151-C100, RRID:AB_2050820
- Product name
- BCMA (human) monoclonal antibody (Vicky-1)
- Antibody type
- Monoclonal
- Antigen
- Recombinant protein fragment
- Description
- Protein G-affinity purified.
- Reactivity
- Human
- Host
- Rat
- Isotype
- IgG
- Antibody clone number
- Vicky-1
- Vial size
- 100 μg
- Storage
- -20°C
- Handling
- Avoid freeze/thaw cycles.
Submitted references The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.
Autoantibody-producing RP105(-) B cells, from patients with systemic lupus erythematosus, showed more preferential expression of BCMA compared with BAFF-R than normal subjects.
TACI regulates IgA production by APRIL in collaboration with HSPG.
Lyu MA, Rai D, Ahn KS, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Gandhi V, Rosenblum MG
Neoplasia (New York, N.Y.) 2010 May;12(5):366-75
Neoplasia (New York, N.Y.) 2010 May;12(5):366-75
Autoantibody-producing RP105(-) B cells, from patients with systemic lupus erythematosus, showed more preferential expression of BCMA compared with BAFF-R than normal subjects.
Koarada S, Tada Y, Sohma Y, Haruta Y, Suematsu R, Mitamura M, Inoue H, Ehara H, Tokoro Y, Ohta A, Nagasawa K
Rheumatology (Oxford, England) 2010 Apr;49(4):662-70
Rheumatology (Oxford, England) 2010 Apr;49(4):662-70
TACI regulates IgA production by APRIL in collaboration with HSPG.
Sakurai D, Hase H, Kanno Y, Kojima H, Okumura K, Kobata T
Blood 2007 Apr 1;109(7):2961-7
Blood 2007 Apr 1;109(7):2961-7
No comments: Submit comment
Supportive validation
- Submitted by
- Enzo Life Sciences (provider)
- Main image
- Experimental details
- Immunostaining of HEK 293 cells transfected with a human BCMA expression plasmid (left panel), or mock transfected (right panel). Method: 3 days after transfection of cells with the indicated constructs, cells were fixed with acetone or 4% formaldehyde for 5 min. at room temperature. Slides were blocked with normal IgG, and incubated for 1 hour with 5µg/ml MAb to BCMA (human) (Vicky-1) (Prod. No. ALX-804-151) in 1% BSA in 1x PBS. After washes in PBS, samples were incubated with the secondary antibody for 1 hour, washed in PBS and revealed with StreptABComplex/HRP (Vector) and AEC.
- Submitted by
- Enzo Life Sciences (provider)
- Main image
- Experimental details
- Detection of endogenous human BCMA with MAb to BCMA (human) (Vicky-1) (Prod. No. ALX-804-151). Method: U266 cells (2x10E5) were incubated on ice for 30 min. with 0.2µg of MAb to BCMA (human) (Vicky-1) or an isotype control in 25µl FACS buffer (PBS, 5% fetal calf serum, 0.02% azide). The primary antibody was revealed with PAb to Rat IgG (R-PE) and then analyzed by flow cytometry.